Efficacy of somatostatin analogues (SSA) in G3 neuroendocrine neoplasms – A comprehensive analysis among the SwissNET cohort

#3720

Introduction: G3 differentiated neuroendocrine neoplasms (NEN) are divided into G3 NET and NEC depending on their histological appearance and proliferation index. The literature on different systemic treatment options in these G3 entities is scarce especially for use of somatostatin analogues (SSA).

Aim(s): Comparison of tumor characteristics, treatments and outcome of patients with G3 NEN receiving different treatments.

Materials and methods: Retrospective analysis of our cohort involving GEP-NENs, pulmonal or unknown origin from 07/14 – 03/22. Site of origin, tumor grading, time to diagnosis / treatment, choice of treatment and survival was assessed.

Conference:

Presenting Author: Siebenhüner A

Authors: Siebenhüner A, Christ E, Kollar A,

Keywords: neuroendocrine neoplasm, neuroendocrine tumor G3, neuroendocrine carcinoma G3, registry, somatostatin analogues, survival,